Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients

Mary R. Welch, Christian Grommes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

AIMS: Type 2 diabetes mellitus (DM2) affects 10% of the population, but little is known about how DM2 and antidiabetic medication impact glioblastoma (GBM) patients.

PATIENTS & METHODS: We retrospectively reviewed GBM patients with DM2 seen at a single institution from 1998 to 2010.

RESULTS: Of 988 GBMs, 124 (12.6%) were affected by DM2. Thirty-four developed DM2 after steroid use and 89 had pre-existing DM2. Median overall survival among diabetic GBMs was 10 months compared with 13 months among nondiabetics. Only 15% of diabetic patients achieved sustained steroid taper. Sixty-seven (54%) were managed with a single antidiabetic medication and, within this monotherapy group, Karnofsky Performance Score, resection status, steroid dependency and metformin use were the most important predictors of survival on multivariate analysis.

CONCLUSION: The prevalence of DM2 among GBMs is similar to that of the general population. A more aggressive approach to steroid tapering and the choice of antidiabetic drug may improve survival within this patient population.

Original languageEnglish (US)
Pages (from-to)237-246
Number of pages10
JournalCNS oncology
Volume2
Issue number3
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Glioblastoma
Hypoglycemic Agents
Steroids
Survival
Population
Metformin
Therapeutics
Type 2 Diabetes Mellitus
Multivariate Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients. / Welch, Mary R.; Grommes, Christian.

In: CNS oncology, Vol. 2, No. 3, 01.05.2013, p. 237-246.

Research output: Contribution to journalArticle

@article{09b3737b6e2d492d8fa45b0bafecf9ee,
title = "Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients",
abstract = "AIMS: Type 2 diabetes mellitus (DM2) affects 10{\%} of the population, but little is known about how DM2 and antidiabetic medication impact glioblastoma (GBM) patients.PATIENTS & METHODS: We retrospectively reviewed GBM patients with DM2 seen at a single institution from 1998 to 2010.RESULTS: Of 988 GBMs, 124 (12.6{\%}) were affected by DM2. Thirty-four developed DM2 after steroid use and 89 had pre-existing DM2. Median overall survival among diabetic GBMs was 10 months compared with 13 months among nondiabetics. Only 15{\%} of diabetic patients achieved sustained steroid taper. Sixty-seven (54{\%}) were managed with a single antidiabetic medication and, within this monotherapy group, Karnofsky Performance Score, resection status, steroid dependency and metformin use were the most important predictors of survival on multivariate analysis.CONCLUSION: The prevalence of DM2 among GBMs is similar to that of the general population. A more aggressive approach to steroid tapering and the choice of antidiabetic drug may improve survival within this patient population.",
author = "Welch, {Mary R.} and Christian Grommes",
year = "2013",
month = "5",
day = "1",
doi = "10.2217/cns.13.12",
language = "English (US)",
volume = "2",
pages = "237--246",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients

AU - Welch, Mary R.

AU - Grommes, Christian

PY - 2013/5/1

Y1 - 2013/5/1

N2 - AIMS: Type 2 diabetes mellitus (DM2) affects 10% of the population, but little is known about how DM2 and antidiabetic medication impact glioblastoma (GBM) patients.PATIENTS & METHODS: We retrospectively reviewed GBM patients with DM2 seen at a single institution from 1998 to 2010.RESULTS: Of 988 GBMs, 124 (12.6%) were affected by DM2. Thirty-four developed DM2 after steroid use and 89 had pre-existing DM2. Median overall survival among diabetic GBMs was 10 months compared with 13 months among nondiabetics. Only 15% of diabetic patients achieved sustained steroid taper. Sixty-seven (54%) were managed with a single antidiabetic medication and, within this monotherapy group, Karnofsky Performance Score, resection status, steroid dependency and metformin use were the most important predictors of survival on multivariate analysis.CONCLUSION: The prevalence of DM2 among GBMs is similar to that of the general population. A more aggressive approach to steroid tapering and the choice of antidiabetic drug may improve survival within this patient population.

AB - AIMS: Type 2 diabetes mellitus (DM2) affects 10% of the population, but little is known about how DM2 and antidiabetic medication impact glioblastoma (GBM) patients.PATIENTS & METHODS: We retrospectively reviewed GBM patients with DM2 seen at a single institution from 1998 to 2010.RESULTS: Of 988 GBMs, 124 (12.6%) were affected by DM2. Thirty-four developed DM2 after steroid use and 89 had pre-existing DM2. Median overall survival among diabetic GBMs was 10 months compared with 13 months among nondiabetics. Only 15% of diabetic patients achieved sustained steroid taper. Sixty-seven (54%) were managed with a single antidiabetic medication and, within this monotherapy group, Karnofsky Performance Score, resection status, steroid dependency and metformin use were the most important predictors of survival on multivariate analysis.CONCLUSION: The prevalence of DM2 among GBMs is similar to that of the general population. A more aggressive approach to steroid tapering and the choice of antidiabetic drug may improve survival within this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84925883672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925883672&partnerID=8YFLogxK

U2 - 10.2217/cns.13.12

DO - 10.2217/cns.13.12

M3 - Article

C2 - 25054464

AN - SCOPUS:84925883672

VL - 2

SP - 237

EP - 246

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 3

ER -